A Phase 2 interventional study of GSK1278863 and Placebo in Anaemia, sponsored by GlaxoSmithKline. Completed at 107 sites in 16 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2018-06-08.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.
Among the 30 studies testing GSK1278863 in Anemia, this one is the 9th largest by enrollment, is one of 3 that started in 2013, is one of 10 in phase 2, and was the 6th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:
GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 216 is above the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 76 across the 30 interventional studies. Of the 29 that completed or were terminated, 23 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 30 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
35 studies in Anemia by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 35 finished, 25 (71%) have results posted.
Among the 35 studies in Anemia by GlaxoSmithKline, this one is the 10th largest by enrollment, is one of 3 that started in 2013, is one of 11 in phase 2, and was the 11th registered.
GlaxoSmithKline’s Anemia studies by the year they started, since 2006.
1 of the studies testing GSK1278863 in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07300111Phase 3Qilu Pharmaceutical Co., Ltd.A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies testing GSK1278863 in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 35 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is intended to evaluate the dose-response relationship of GSK1278863 over the first 4 weeks of treatment and evaluate the safety and efficacy of GSK1278863 over 24 weeks to maintain hemoglobin (Hgb) level in hemodialysis-dependent (HDD) subjects with anemia associated with chronic kidney disease (CKD) who are switched from a stable dose of recombinant human erythropoietin (rhEPO). The data generated will enable selection of the starting dose(s) and optimize dose adjustment regimen(s) for Phase 3 clinical trials.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will take GSK1278863 4 mg blinded once daily (OD) orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
Drug: GSK1278863
Subjects will take GSK1278863 6 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
Drug: GSK1278863
Subjects will take GSK1278863 8 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
Drug: GSK1278863
Subjects will take GSK1278863 10 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
Drug: GSK1278863
Subjects will take GSK1278863 12 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
Drug: GSK1278863
Subjects will take GSK1278863 matching placebo blinded OD orally for 4 weeks with a glass of water. From Week 4, rhEPO will be administered and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
Drug: Placebo · Drug: rhEPO
Film coated tablets containing 1 mg, 2 mg, 5 mg, or 25 mg of GSK1278863
Matching placebo tablet for GSK1278863
rhEPO will be procured from local market
Change From Baseline in Hemoglobin (Hgb) at Week 4
Baseline Hgb value was the average of three Hgb values taken during screening period at Week (W) -4, W-2 and Day 1. Change from Baseline in Hgb was calculated as W4 value minus the Baseline value. To model the dose-response relationship a four-parameter Emax model was used. The dose response dataset was based on all non-missing data collected up to W4. Participants (par.) who had a Week 2 Hgb measurement, but a missing Week 4 Hgb measurement were included with a change from Baseline at Week 4 value imputed as twice the change from Baseline at Week 2. E0 is the expected Hgb change from Baseline for a par. receiving placebo and experiencing the average Hgb Baseline observed in the study. Emax is the expected Hgb change from Baseline for a par. receiving the highest dose above which no further increase in response can be achieved. ED50 is the dose that attains the intermediate response. Gamma is the slope parameter. Alpha is the coefficient of the model covariate for centred Baseline.
Time frame: Baseline (Week -4, Week-2 and Day 1) and Week 4
Hgb Concentration at Week 24
Hgb values measured at Week 24 are presented.
Time frame: Week 24
Percentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24
The percentage of time in Hgb target range between Weeks 20 and 24 for a participant was calculated by dividing the total number of days that Hgb was within the target range (10.0 to 11.5 g/dL) while on treatment during Weeks 20 to 24 (using linear interpolation) by the total number of days the participant remained on treatment during the defined period. Similarly, percentage of time above Hgb target range and percentage of time below Hgb target range were calculated.
Time frame: Week 20 to Week 24
Number of Participants With Hgb in the Target Range at Week 24
The number of participants with Hgb in the target range of 10.0 to 11.5 g/dL at Week 24 was recorded for each arm.
Time frame: Week 24
Number of Participants Reaching Pre-defined Hgb Stopping Criteria
The number of participants who reached the Hgb stopping criteria of Hgb concentration \<7.5 g/dL were presented.
Time frame: Up to 24 weeks
Maximum Observed Change From Baseline in Erythropoietin (EPO)
Blood samples for control arm were collected on Day 1 (pre-dose), Week 4 (5-15 minutes post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 5-15 minutes post-dose), Week 24 (pre-dose), and Week 28 (pre-dose) for EPO measurement. Blood samples for GSK1278863 arms were collected on Day 1 (pre-dose), Week 4 (6-12 hours post-dose), Week 4 (7-13, 8-14, 9-15, hours post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 3 hour post-dose) Week 24 (pre-dose), and Week 28 (pre-dose) for EPO measurement. The maximum observed change from baseline in EPO was recorded for each arm. Baseline value for EPO is the pre-dose value on Day 1. Change from Baseline in EPO was calculated as the individual post-dose values minus the Baseline value.
Time frame: Baseline (Day 1) to Week 28
Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)
Blood samples for control arm were collected on Day 1 (pre-dose), Week 4 (5-15 minutes post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 5-15 minutes post-dose), Week 24 (pre-dose), and Week 28 (pre-dose) for VEGF measurement. Blood samples for GSK1278863 arms were collected on Day 1 (pre-dose), Week 4 (6-12 hours post-dose), Week 4 (7-13, 8-14, 9-15, hours post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 3 hour post-dose) Week 24 (pre-dose), and Week 28 (pre-dose) for VEGF measurement. The maximum observed percent change from Baseline in VEGF was recorded for each arm. Baseline value for VEGF is the pre-dose value on Day 1. Percent change from Baseline was calculated as 100 multiplied by exponential of mean change in log scale minus 1.
Time frame: Baseline (Day 1) to Week 28
Population Plasma PK Parameters of GSK1278863 and Metabolites
Blood samples were collected for individual plasma GSK1278863and metabolite (GSK2391220, GSK2499166, GSK2531403, GSK2531400, GSK2531399, and GSK2531398) concentrations measurement on Day (D) 1 (pre-dose \[PrD), at Week (W) 4 (6-12, 7-13, 8-14, and 9-15 hour \[hr\] post-dose \[PoD), and at W20 (PrD, 1, 2, and 3 hour PoD). Pharmacokinetic population: All participants from whom a PK sample has been obtained and analyzed.
Time frame: Day 1, Week 4, and Week 20
Percent Change From Baseline in Hepcidin at Week 24
Hepcidin is a regulator of iron metabolism. Baseline value for transferrin saturation is the pre-dose value on Day 1. Percent change from Baseline was calculated as 100 multiplied by exponential of mean change in log scale minus 1.
Time frame: Baseline (Day 1) and Week 24
Change From Baseline in Ferritin at Week 24
Baseline value for ferritin is the pre-dose value on Day 1. Change from Baseline in ferritin was calculated as the Week 24 value minus the Baseline value.
Time frame: Baseline (Day 1) and Week 24
Change From Baseline in Transferrin at Week 24
Baseline value for transferrin is the pre-dose value on Day 1. Change from Baseline in transferrin was calculated as the Week 24 value minus the Baseline value.
Time frame: Baseline (Day 1) and Week 24
Percent Change From Baseline in Transferrin Saturation at Week 24
Transferrin saturation is measured as a percentage, it is the ratio of serum iron and total iron-binding capacity, multiplied by 100. Baseline value for transferrin saturation is the pre-dose value on Day 1. Percent change from Baseline =: 100\*(exp(Mean change log scale)-1).
Time frame: Baseline (Day 1) and Week 24
Change From Baseline in Total Iron at Week 24
Baseline value for total iron is the pre-dose value on Day 1. Change from Baseline in total iron was calculated as the Week 24 value minus the Baseline value.
Time frame: Baseline (Day 1) and Week 24
Change From Baseline in Total Iron Binding Capacity at Week 24
Total iron-binding capacity is a medical laboratory test that measures the blood's capacity to bind iron with transferrin. Baseline value for total iron binding capacity is the pre-dose value on Day 1. Change from Baseline in total iron binding capacity was calculated as the Week 24 value minus the Baseline value.
Time frame: Baseline (Day 1) and Week 24
Change From Baseline in Reticulocyte Hemoglobin at Week 24
Baseline value for reticulocyte hemoglobin is the pre-dose value on Day 1. Change from Baseline in reticulocyte hemoglobin was calculated as the Week 24 value minus the Baseline value.
Time frame: Baseline (Day 1) and Week 24
Change From Baseline in Hematocrit at Week 24
Hematocrit is the ratio of the volume of red blood cells to the total volume of blood. Baseline value for hematocrit is the pre-dose value on Day 1. Change from Baseline in hematocrit was calculated as the Week 24 value minus the Baseline value.
Time frame: Baseline (Day 1) and Week 24
Change From Baseline in Red Blood Cells at Week 24
Baseline value for red blood cells is the pre-dose value on Day 1. Change from Baseline in red blood cells was calculated as the Week 24 value minus the Baseline value.
Time frame: Baseline (Day 1) and Week 24
Change From Baseline in Reticulocyte Count at Week 24
A reticulocyte count is a blood test that measures the percentage of reticulocytes in the blood. Reticulocytes are slightly immature red blood cells. Baseline value for reticulocyte count is the pre-dose value on Day 1. Change from Baseline in reticulocyte count was calculated as the Week 24 value minus the Baseline value.
Time frame: Baseline (Day 1) and Week 24
Eligible participants were hemodialysis-dependent with anemia associated with chronic kidney disease who were switched from a stable dose of recombinant human erythropoietin (rhEPO).
| Milestone | Control | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | GSK1278863 12 mg |
|---|---|---|---|---|---|---|
| Started | 39 | 39 | 40 | 39 | 40 | 19 |
| Completed | 36 | 30 | 35 | 35 | 37 | 14 |
| Not completed | 3 | 9 | 5 | 4 | 3 | 5 |
| Withdrew: Adverse event | 0 | 1 | 1 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Other-protocol-defined stopping criteria | 0 | 3 | 2 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 4 | 1 | 3 | 1 | 5 |
Baseline Hgb value was the average of three Hgb values taken during screening period at Week (W) -4, W-2 and Day 1. Change from Baseline in Hgb was calculated as W4 value minus the Baseline value. To model the dose-response relationship a four-parameter Emax model was used. The dose response dataset was based on all non-missing data collected up to W4. Participants (par.) who had a Week 2 Hgb measurement, but a missing Week 4 Hgb measurement were included with a change from Baseline at Week 4 value imputed as twice the change from Baseline at Week 2. E0 is the expected Hgb change from Baseline for a par. receiving placebo and experiencing the average Hgb Baseline observed in the study. Emax is the expected Hgb change from Baseline for a par. receiving the highest dose above which no further increase in response can be achieved. ED50 is the dose that attains the intermediate response. Gamma is the slope parameter. Alpha is the coefficient of the model covariate for centred Baseline.
| grams (g)/deciliter (dL) | Control | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | GSK1278863 12 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in Hemoglobin (Hgb) at Week 4 | -0.64 ± 0.829 | -0.24 ± 0.989 | 0.08 ± 1.131 | 0.42 ± 0.796 | 0.64 ± 1.177 | 0.61 ± 1.245 |
Hgb values measured at Week 24 are presented.
| g/dL | Control | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | GSK1278863 12 mg |
|---|---|---|---|---|---|---|
| Hgb Concentration at Week 24 | 10.56 ± 0.974 | 10.29 ± 0.864 | 10.54 ± 1.010 | 10.63 ± 1.099 | 10.28 ± 0.856 | 10.70 ± 0.867 |
The percentage of time in Hgb target range between Weeks 20 and 24 for a participant was calculated by dividing the total number of days that Hgb was within the target range (10.0 to 11.5 g/dL) while on treatment during Weeks 20 to 24 (using linear interpolation) by the total number of days the participant remained on treatment during the defined period. Similarly, percentage of time above Hgb target range and percentage of time below Hgb target range were calculated.
| Percentage of days | Control | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | GSK1278863 12 mg |
|---|---|---|---|---|---|---|
| Percentage of time within target range | 54.59 ± 42.044 | 74.77 ± 38.797 | 57.38 ± 40.505 | 37.46 ± 41.775 | 48.97 ± 42.490 | 55.23 ± 40.350 |
| Percentage of time above target range | 24.65 ± 38.556 | 6.89 ± 22.137 | 17.18 ± 30.446 | 33.15 ± 42.856 | 18.27 ± 33.698 | 26.88 ± 36.154 |
| Percentage of time below target range | 20.76 ± 36.587 | 18.34 ± 35.778 | 25.44 ± 40.120 | 29.39 ± 42.670 | 32.76 ± 43.780 | 17.89 ± 36.836 |
The number of participants with Hgb in the target range of 10.0 to 11.5 g/dL at Week 24 was recorded for each arm.
| Participants | Control | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | GSK1278863 12 mg |
|---|---|---|---|---|---|---|
| Number of Participants With Hgb in the Target Range at Week 24 | 14 | 13 | 16 | 10 | 15 | 8 |
The number of participants who reached the Hgb stopping criteria of Hgb concentration \<7.5 g/dL were presented.
| Participants | Control | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | GSK1278863 12 mg |
|---|---|---|---|---|---|---|
| Number of Participants Reaching Pre-defined Hgb Stopping Criteria | 0 | 0 | 0 | 0 | 0 | 0 |
Blood samples for control arm were collected on Day 1 (pre-dose), Week 4 (5-15 minutes post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 5-15 minutes post-dose), Week 24 (pre-dose), and Week 28 (pre-dose) for EPO measurement. Blood samples for GSK1278863 arms were collected on Day 1 (pre-dose), Week 4 (6-12 hours post-dose), Week 4 (7-13, 8-14, 9-15, hours post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 3 hour post-dose) Week 24 (pre-dose), and Week 28 (pre-dose) for EPO measurement. The maximum observed change from baseline in EPO was recorded for each arm. Baseline value for EPO is the pre-dose value on Day 1. Change from Baseline in EPO was calculated as the individual post-dose values minus the Baseline value.
| international units(IU)/Liter (L) | Control | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | GSK1278863 12 mg |
|---|---|---|---|---|---|---|
| Maximum Observed Change From Baseline in Erythropoietin (EPO) | 1946.45 ± 8456.313 | 48.86 ± 117.050 | 36.63 ± 35.485 | 84.53 ± 225.768 | 82.00 ± 99.660 | 24.63 ± 235.820 |
Blood samples for control arm were collected on Day 1 (pre-dose), Week 4 (5-15 minutes post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 5-15 minutes post-dose), Week 24 (pre-dose), and Week 28 (pre-dose) for VEGF measurement. Blood samples for GSK1278863 arms were collected on Day 1 (pre-dose), Week 4 (6-12 hours post-dose), Week 4 (7-13, 8-14, 9-15, hours post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 3 hour post-dose) Week 24 (pre-dose), and Week 28 (pre-dose) for VEGF measurement. The maximum observed percent change from Baseline in VEGF was recorded for each arm. Baseline value for VEGF is the pre-dose value on Day 1. Percent change from Baseline was calculated as 100 multiplied by exponential of mean change in log scale minus 1.
| Percent change | Control | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | GSK1278863 12 mg |
|---|---|---|---|---|---|---|
| Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF) | 36.02 (16.45 to 58.87) | 36.92 (19.33 to 57.11) | 41.73 (22.65 to 63.77) | 54.91 (37.38 to 74.69) | 50.65 (31.88 to 72.10) | 50.97 (21.49 to 87.60) |
Blood samples were collected for individual plasma GSK1278863and metabolite (GSK2391220, GSK2499166, GSK2531403, GSK2531400, GSK2531399, and GSK2531398) concentrations measurement on Day (D) 1 (pre-dose \[PrD), at Week (W) 4 (6-12, 7-13, 8-14, and 9-15 hour \[hr\] post-dose \[PoD), and at W20 (PrD, 1, 2, and 3 hour PoD). Pharmacokinetic population: All participants from whom a PK sample has been obtained and analyzed.
| nanograms (ng)/milliliter (mL) | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | GSK1278863 12 mg |
|---|---|---|---|---|---|
| GSK1278863, D1, PrD, n=39, 40, 39, 40, 18 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| GSK1278863, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15 | 6.3 ± 10.04 | 9.3 ± 19.06 | 7.7 ± 18.46 | 25.4 ± 53.37 | 9.0 ± 18.80 |
| GSK1278863, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15 | 10.6 ± 25.15 | 16.3 ± 57.24 | 8.7 ± 19.85 | 19.9 ± 42.65 | 8.0 ± 16.92 |
| GSK1278863, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15 | 7.5 ± 16.80 | 8.1 ± 23.76 | 5.6 ± 11.75 | 12.7 ± 28.60 | 4.6 ± 6.87 |
| GSK1278863, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15 | 6.8 ± 14.53 | 4.6 ± 10.49 | 4.4 ± 9.19 | 11.3 ± 25.36 | 11.2 ± 33.59 |
| GSK1278863, W20, PrD, n=23, 28, 27, 23, 14 | 2.3 ± 6.44 | 0.7 ± 2.55 | 0.9 ± 2.82 | 7.9 ± 30.99 | 6.6 ± 20.22 |
| GSK1278863, W20, 1 hr PoD, n=23, 27, 27, 24, 13 | 25.9 ± 35.74 | 37.6 ± 53.77 | 88.2 ± 153.06 | 58.5 ± 85.91 | 65.2 ± 127.21 |
| GSK1278863, W20, 2 hr PoD, n=23, 27, 27, 24, 13 | 34.2 ± 31.76 | 52.4 ± 53.32 | 62.8 ± 85.37 | 82.7 ± 117.97 | 63.3 ± 102.15 |
| GSK1278863, W20, 3 hr PoD, n=23, 27, 27, 24, 14 | 43.6 ± 58.36 | 39.2 ± 44.59 | 44.1 ± 70.53 | 71.2 ± 110.91 | 65.8 ± 100.80 |
| GSK2391220, D1, PrD, n=39, 40, 39, 40, 18 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| GSK2391220, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15 | 9.1 ± 6.68 | 12.9 ± 8.32 | 18.5 ± 13.72 | 20.1 ± 12.32 | 21.3 ± 17.34 |
| GSK2391220, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15 | 5.1 ± 4.22 | 6.7 ± 5.51 | 10.3 ± 8.55 | 10.9 ± 6.37 | 13.1 ± 12.44 |
| GSK2391220, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15 | 3.8 ± 3.66 | 4.5 ± 4.16 | 7.4 ± 6.44 | 7.4 ± 4.51 | 7.2 ± 6.97 |
| GSK2391220, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15 | 3.3 ± 3.76 | 3.3 ± 3.15 | 5.3 ± 4.86 | 5.4 ± 3.63 | 6.6 ± 5.72 |
| GSK2391220, W20, PrD, n=23, 28, 27, 23, 14 | 5.0 ± 7.72 | 3.2 ± 4.97 | 4.1 ± 5.84 | 4.6 ± 9.29 | 3.5 ± 6.69 |
| GSK2391220, W20, 1 hr PoD, n=23, 27, 27, 24, 13 | 3.9 ± 5.59 | 2.7 ± 3.60 | 4.3 ± 4.90 | 5.0 ± 8.10 | 2.6 ± 3.64 |
| GSK2391220, W20, 2 hr PoD, n=23, 27, 27, 24, 13 | 5.4 ± 5.58 | 4.5 ± 4.96 | 6.5 ± 6.93 | 8.1 ± 10.33 | 4.9 ± 4.08 |
| GSK2391220, W20, 3 hr PoD, n=23, 27, 27, 24, 14 | 5.3 ± 4.64 | 5.0 ± 5.26 | 7.3 ± 6.69 | 8.2 ± 6.52 | 6.1 ± 4.92 |
| GSK2487818, D1, PrD, n=39, 40, 39, 40, 18 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| GSK2487818, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15 | 3.1 ± 2.82 | 4.1 ± 4.47 | 5.7 ± 6.31 | 7.2 ± 6.57 | 5.2 ± 4.66 |
| GSK2487818, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15 | 1.8 ± 1.75 | 2.6 ± 3.81 | 3.5 ± 4.55 | 4.1 ± 3.73 | 3.7 ± 4.61 |
| GSK2487818, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15 | 1.5 ± 1.67 | 1.9 ± 3.21 | 2.7 ± 3.58 | 2.7 ± 2.44 | 1.7 ± 1.68 |
| GSK2487818, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15 | 1.4 ± 1.88 | 1.5 ± 2.46 | 1.9 ± 2.85 | 1.9 ± 1.92 | 1.9 ± 2.21 |
| GSK2487818, W20, PrD, n=23, 28, 27, 23, 14 | 1.2 ± 3.38 | 0.5 ± 1.05 | 0.7 ± 1.28 | 1.3 ± 4.09 | 0.7 ± 1.84 |
| GSK2487818, W20, 1 hr PoD, n=23, 27, 27, 24, 13 | 2.0 ± 3.82 | 1.3 ± 1.73 | 2.7 ± 3.97 | 3.4 ± 5.88 | 1.0 ± 1.34 |
| GSK2487818, W20, 2 hr PoD, n=23, 27, 27, 24, 13 | 3.8 ± 4.58 | 3.6 ± 4.36 | 5.0 ± 5.82 | 6.3 ± 8.04 | 3.7 ± 3.28 |
| GSK2487818, W20, 3 hr PoD, n=23, 27, 27, 24, 14 | 3.9 ± 3.49 | 4.3 ± 4.76 | 5.7 ± 5.28 | 6.5 ± 5.05 | 5.0 ± 4.43 |
| GSK2506102, D1, PrD, n=39, 40, 39, 40, 18 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| GSK2506102, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15 | 3.2 ± 1.98 | 4.9 ± 2.68 | 6.6 ± 4.16 | 7.6 ± 4.30 | 9.0 ± 6.19 |
| GSK2506102, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15 | 1.8 ± 1.31 | 2.5 ± 1.71 | 3.7 ± 2.60 | 4.1 ± 2.15 | 5.4 ± 4.10 |
| GSK2506102, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15 | 1.3 ± 1.07 | 1.6 ± 1.16 | 2.6 ± 1.94 | 2.9 ± 1.68 | 2.9 ± 2.24 |
| GSK2506102, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15 | 1.1 ± 1.16 | 1.2 ± 0.88 | 1.9 ± 1.52 | 2.1 ± 1.23 | 2.7 ± 2.04 |
| GSK2506102, W20, PrD, n=23, 28, 27, 23, 14 | 2.3 ± 1.99 | 1.9 ± 2.05 | 2.3 ± 2.09 | 2.6 ± 2.87 | 2.2 ± 2.87 |
| GSK2506102, W20, 1 hr PoD, n=23, 27, 27, 24, 13 | 1.4 ± 1.27 | 1.1 ± 1.40 | 1.4 ± 1.22 | 1.8 ± 2.12 | 1.4 ± 1.57 |
| GSK2506102, W20, 2 hr PoD, n=23, 27, 27, 24, 13 | 1.5 ± 1.25 | 1.2 ± 1.24 | 1.8 ± 1.72 | 2.2 ± 2.53 | 1.6 ± 1.37 |
| GSK2506102, W20, 3 hr PoD, n=23, 27, 27, 24, 14 | 1.4 ± 1.12 | 1.3 ± 1.26 | 1.9 ± 1.53 | 2.1 ± 1.66 | 1.7 ± 1.42 |
| GSK2531398, D1, PrD, n=39, 40, 39, 40, 18 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| GSK2531398, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15 | 3.4 ± 2.46 | 4.9 ± 3.11 | 6.9 ± 4.52 | 8.0 ± 4.87 | 7.9 ± 5.75 |
| GSK2531398, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15 | 2.0 ± 1.72 | 2.7 ± 2.41 | 4.0 ± 2.97 | 4.5 ± 2.70 | 4.9 ± 4.05 |
| GSK2531398, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15 | 1.5 ± 1.46 | 1.8 ± 1.86 | 2.9 ± 2.30 | 3.1 ± 1.95 | 2.5 ± 1.78 |
| GSK2531398, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15 | 1.4 ± 1.58 | 1.4 ± 1.49 | 2.1 ± 1.99 | 2.2 ± 1.38 | 2.3 ± 1.42 |
| GSK2531398, W20, PrD, n=23, 28, 27, 23, 14 | 1.5 ± 2.31 | 1.2 ± 2.03 | 1.4 ± 1.93 | 1.6 ± 3.80 | 1.2 ± 2.67 |
| GSK2531398, W20, 1 hr PoD, n=23, 27, 27, 24, 13 | 1.3 ± 1.89 | 1.0 ± 1.34 | 1.6 ± 1.81 | 2.0 ± 3.58 | 1.0 ± 1.45 |
| GSK2531398, W20, 2 hr PoD, n=23, 27, 27, 24, 13 | 2.1 ± 2.24 | 1.9 ± 2.09 | 2.9 ± 3.28 | 3.5 ± 4.69 | 2.1 ± 1.79 |
| GSK2531398, W20, 3 hr PoD, n=23, 27, 27, 24, 14 | 2.3 ± 2.04 | 2.2 ± 2.22 | 3.3 ± 2.89 | 3.8 ± 3.10 | 2.8 ± 2.34 |
| GSK2531401, D1, PrD, n=39, 40, 39, 40, 18 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.02 |
| GSK2531401, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15 | 9.9 ± 8.00 | 14.7 ± 10.02 | 22.2 ± 14.71 | 24.5 ± 18.27 | 29.1 ± 24.55 |
| GSK2531401, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15 | 5.4 ± 4.49 | 7.1 ± 5.53 | 11.8 ± 8.49 | 13.1 ± 9.50 | 17.3 ± 16.03 |
| GSK2531401, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15 | 4.0 ± 3.63 | 4.5 ± 3.50 | 8.1 ± 5.74 | 9.0 ± 7.05 | 10.1 ± 10.61 |
| GSK2531401, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15 | 3.3 ± 3.36 | 3.2 ± 2.35 | 5.9 ± 4.66 | 6.3 ± 4.90 | 8.7 ± 8.72 |
| GSK2531401, W20, PrD, n=23, 28, 27, 23, 14 | 7.7 ± 7.71 | 7.3 ± 7.34 | 7.9 ± 7.37 | 9.3 ± 10.95 | 7.2 ± 10.04 |
| GSK2531401, W20, 1 hr PoD, n=23, 27, 27, 24, 13 | 4.2 ± 4.52 | 4.0 ± 6.77 | 4.7 ± 4.18 | 5.6 ± 7.48 | 4.5 ± 5.44 |
| GSK2531401, W20, 2 hr PoD, n=23, 27, 27, 24, 13 | 4.2 ± 4.44 | 3.6 ± 4.50 | 4.8 ± 4.08 | 6.1 ± 8.21 | 4.4 ± 4.41 |
| GSK2531401, W20, 3 hr PoD, n=23, 27, 27, 24, 14 | 4.1 ± 4.07 | 3.6 ± 4.55 | 5.0 ± 4.64 | 5.5 ± 5.38 | 4.5 ± 4.28 |
| GSK2531403, D1, PrD, n=39, 40, 39, 40, 18 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| GSK2531403, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15 | 11.4 ± 7.47 | 17.0 ± 9.89 | 23.1 ± 15.22 | 25.4 ± 14.25 | 28.8 ± 21.46 |
| GSK2531403, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15 | 6.3 ± 4.84 | 8.6 ± 6.43 | 13.1 ± 9.73 | 13.9 ± 7.66 | 17.4 ± 14.72 |
| GSK2531403, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15 | 4.7 ± 4.23 | 5.7 ± 4.63 | 9.3 ± 7.37 | 9.6 ± 5.50 | 9.9 ± 9.05 |
| GSK2531403, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15 | 4.1 ± 4.60 | 4.1 ± 3.41 | 6.7 ± 5.50 | 6.9 ± 4.25 | 8.9 ± 7.79 |
| GSK2531403, W20, PrD, n=23, 28, 27, 23, 14 | 7.8 ± 8.53 | 6.0 ± 8.08 | 6.7 ± 6.74 | 7.8 ± 11.14 | 6.2 ± 8.78 |
| GSK2531403, W20, 1 hr PoD, n=23, 27, 27, 24, 13 | 4.9 ± 5.56 | 3.8 ± 4.88 | 5.0 ± 4.71 | 6.2 ± 8.65 | 4.0 ± 4.80 |
| GSK2531403, W20, 2 hr PoD, n=23, 27, 27, 24, 13 | 5.7 ± 5.43 | 4.7 ± 4.91 | 6.8 ± 6.54 | 8.5 ± 10.83 | 5.5 ± 4.58 |
| GSK2531403, W20, 3 hr PoD, n=23, 27, 27, 24, 14 | 5.5 ± 4.52 | 5.1 ± 5.18 | 7.4 ± 6.43 | 8.4 ± 6.86 | 6.5 ± 5.14 |
Hepcidin is a regulator of iron metabolism. Baseline value for transferrin saturation is the pre-dose value on Day 1. Percent change from Baseline was calculated as 100 multiplied by exponential of mean change in log scale minus 1.
| Percent change | Control | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | GSK1278863 12 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Hepcidin at Week 24 | 3.63 (-20.39 to 34.89) | -17.39 (-42.36 to 18.40) | -11.85 (-26.47 to 5.67) | -30.28 (-48.08 to -6.37) | -6.91 (-28.69 to 21.52) | -42.13 (-62.82 to -9.95) |
Baseline value for ferritin is the pre-dose value on Day 1. Change from Baseline in ferritin was calculated as the Week 24 value minus the Baseline value.
| Micrograms/Liter | Control | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | GSK1278863 12 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in Ferritin at Week 24 | 56.8 ± 214.27 | -29.4 ± 357.10 | -50.4 ± 408.99 | -95.6 ± 304.61 | -20.2 ± 227.34 | -125.2 ± 354.64 |
Baseline value for transferrin is the pre-dose value on Day 1. Change from Baseline in transferrin was calculated as the Week 24 value minus the Baseline value.
| grams (g)/Liter (L) | Control | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | GSK1278863 12 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in Transferrin at Week 24 | -0.133 ± 0.2903 | 0.238 ± 0.3709 | 0.198 ± 0.2891 | 0.226 ± 0.2706 | 0.249 ± 0.3213 | 0.393 ± 0.3165 |
Transferrin saturation is measured as a percentage, it is the ratio of serum iron and total iron-binding capacity, multiplied by 100. Baseline value for transferrin saturation is the pre-dose value on Day 1. Percent change from Baseline =: 100\*(exp(Mean change log scale)-1).
| Percent change | Control | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | GSK1278863 12 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Transferrin Saturation at Week 24 | -9.0 (-27.3 to 13.9) | -3.7 (-22.9 to 20.4) | -12.1 (-23.4 to 0.9) | -8.3 (-22.9 to 9.0) | 8.2 (-7.7 to 26.8) | -2.5 (-16.0 to 13.2) |
Baseline value for total iron is the pre-dose value on Day 1. Change from Baseline in total iron was calculated as the Week 24 value minus the Baseline value.
| Micromoles/Liter | Control | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | GSK1278863 12 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in Total Iron at Week 24 | -0.8 ± 7.64 | 0.9 ± 9.75 | 0.3 ± 5.20 | 0.2 ± 6.51 | 2.0 ± 3.96 | 1.6 ± 3.18 |
Total iron-binding capacity is a medical laboratory test that measures the blood's capacity to bind iron with transferrin. Baseline value for total iron binding capacity is the pre-dose value on Day 1. Change from Baseline in total iron binding capacity was calculated as the Week 24 value minus the Baseline value.
| Micromoles/Liter | Control | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | GSK1278863 12 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in Total Iron Binding Capacity at Week 24 | -2.0 ± 4.48 | 6.0 ± 7.93 | 4.2 ± 6.79 | 6.6 ± 5.75 | 4.8 ± 6.25 | 6.2 ± 6.44 |
Baseline value for reticulocyte hemoglobin is the pre-dose value on Day 1. Change from Baseline in reticulocyte hemoglobin was calculated as the Week 24 value minus the Baseline value.
| Picogram | Control | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | GSK1278863 12 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in Reticulocyte Hemoglobin at Week 24 | -0.19 ± 1.610 | -0.28 ± 1.948 | -0.62 ± 2.046 | -0.42 ± 1.458 | -0.51 ± 1.377 | -0.63 ± 1.119 |
Hematocrit is the ratio of the volume of red blood cells to the total volume of blood. Baseline value for hematocrit is the pre-dose value on Day 1. Change from Baseline in hematocrit was calculated as the Week 24 value minus the Baseline value.
| Ratio | Control | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | GSK1278863 12 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in Hematocrit at Week 24 | -0.0028 ± 0.04358 | -0.0096 ± 0.04073 | 0.0020 ± 0.03579 | 0.0043 ± 0.04254 | -0.0021 ± 0.02678 | 0.0108 ± 0.03557 |
Baseline value for red blood cells is the pre-dose value on Day 1. Change from Baseline in red blood cells was calculated as the Week 24 value minus the Baseline value.
| 10^12 cells/Liter | Control | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | GSK1278863 12 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in Red Blood Cells at Week 24 | 0.01 ± 0.460 | -0.06 ± 0.396 | 0.04 ± 0.374 | 0.07 ± 0.399 | 0.03 ± 0.300 | 0.17 ± 0.366 |
A reticulocyte count is a blood test that measures the percentage of reticulocytes in the blood. Reticulocytes are slightly immature red blood cells. Baseline value for reticulocyte count is the pre-dose value on Day 1. Change from Baseline in reticulocyte count was calculated as the Week 24 value minus the Baseline value.
| Percentage of reticulocytes in blood | Control | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | GSK1278863 12 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in Reticulocyte Count at Week 24 | 0.40 ± 0.663 | 0.16 ± 1.162 | 0.18 ± 0.571 | 0.03 ± 0.684 | -0.15 ± 0.838 | 0.10 ± 0.527 |
Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study treatment and until the follow up contact (up to 28 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Control | — | 11/39 (28.2%) | 17/39 (43.6%) |
| GSK1278863 4 mg | — | 10/39 (25.6%) | 28/39 (71.8%) |
| GSK1278863 6 mg | — | 8/40 (20%) | 17/40 (42.5%) |
| GSK1278863 8 mg | — | 8/39 (20.5%) | 25/39 (64.1%) |
| GSK1278863 10 mg | — | 11/40 (27.5%) | 21/40 (52.5%) |
| GSK1278863 12 mg | — | 1/19 (5.3%) | 6/19 (31.6%) |
| Event | Control | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | GSK1278863 12 mg |
|---|---|---|---|---|---|---|
| Device related sepsisInfections and infestations | 0/39 | 0/39 | 0/40 | 0/39 | 0/40 | 1/19 |
| Cardiac arrestCardiac disorders | 0/39 | 2/39 | 0/40 | 0/39 | 1/40 | 0/19 |
| GastroenteritisInfections and infestations | 0/39 | 1/39 | 0/40 | 2/39 | 0/40 | 0/19 |
| Acute myocardial infarctionCardiac disorders | 0/39 | 1/39 | 1/40 | 0/39 | 1/40 | 0/19 |
| Angina pectorisCardiac disorders | 0/39 | 1/39 | 0/40 | 0/39 | 1/40 | 0/19 |
| Angina unstableCardiac disorders | 0/39 | 1/39 | 0/40 | 0/39 | 1/40 | 0/19 |
| Atrioventricular blockCardiac disorders | 1/39 | 0/39 | 0/40 | 0/39 | 0/40 | 0/19 |
| Cardiac failureCardiac disorders | 0/39 | 0/39 | 1/40 | 1/39 | 0/40 | 0/19 |
| Cardiac failure acuteCardiac disorders | 0/39 | 1/39 | 0/40 | 0/39 | 0/40 | 0/19 |
| Sick sinus syndromeCardiac disorders | 1/39 | 0/39 | 0/40 | 0/39 | 0/40 | 0/19 |
| Event | Control | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | GSK1278863 12 mg |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 2/39 | 5/39 | 2/40 | 7/39 | 2/40 | 1/19 |
| NauseaGastrointestinal disorders | 0/39 | 6/39 | 3/40 | 2/39 | 1/40 | 1/19 |
| HypertensionVascular disorders | 1/39 | 6/39 | 0/40 | 2/39 | 4/40 | 0/19 |
| NasopharyngitisInfections and infestations | 5/39 | 5/39 | 6/40 | 3/39 | 4/40 | 1/19 |
| Abdominal painGastrointestinal disorders | 0/39 | 4/39 | 0/40 | 1/39 | 0/40 | 0/19 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/39 | 2/39 | 1/40 | 4/39 | 1/40 | 0/19 |
| Back painMusculoskeletal and connective tissue disorders | 4/39 | 0/39 | 2/40 | 1/39 | 4/40 | 0/19 |
| HeadacheNervous system disorders | 2/39 | 4/39 | 1/40 | 2/39 | 2/40 | 0/19 |
| VomitingGastrointestinal disorders | 1/39 | 3/39 | 2/40 | 1/39 | 2/40 | 0/19 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/39 | 0/39 | 0/40 | 3/39 | 1/40 | 0/19 |
| Age, Continuous(Years) | Control | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | GSK1278863 12 mg | Total |
|---|---|---|---|---|---|---|---|
| Years | 59.7 ± 18.74 | 58.7 ± 13.33 | 63.5 ± 14.00 | 60.1 ± 10.36 | 55.4 ± 15.50 | 59.9 ± 13.26 | 59.5 ± 14.58 |
| Sex: Female, Male(Participants) | Control | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | GSK1278863 12 mg | Total |
|---|---|---|---|---|---|---|---|
| Female | 13 | 15 | 12 | 15 | 17 | 8 | 80 |
| Male | 26 | 24 | 28 | 24 | 23 | 11 | 136 |
| Race/Ethnicity, Customized(Participants) | Control | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | GSK1278863 12 mg | Total |
|---|---|---|---|---|---|---|---|
| White | 23 | 28 | 28 | 28 | 31 | 12 | 150 |
| African American | 7 | 4 | 5 | 3 | 4 | 4 | 27 |
| Asian | 7 | 6 | 7 | 7 | 5 | 3 | 35 |
| Other | 2 | 1 | 0 | 1 | 0 | 0 | 4 |
Showing the first 100 of 107 sites across 16 countries. Choose a country and city above to see the rest.
The record gives a start of Nov 2013, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2017, 2 years after primary completion. A results delay was requested in Jun 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK1278863